Business
PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market
TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,128,012, expiring May 14, 2041, for the use of ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS). This newly issued patent significantly strengthens the Company’s intellec
About this update from Pharmather Holdings Ltd
[{"type":"image","alt":"PharmaTher Holdings Ltd.","displaySize":"","headline":null,"caption":"PharmaTher Holdings Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/fc3dbb93541a72465e5a664075d3f16e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DcQmlcIkLQG4xagzIFe8Vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fc3dbb93541a72465e5a664075d3f16e","width":300,"height":91}},"lazy":false},{"type":"text","content":"TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,128,012, expiring May 14, 2041, for the use of ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS).","length":446,"tagName":"p"},{"type":"text","content":"This newly issued patent significantly strengthens the Company’s intellectual property portfolio and provides robust protection for its clinical development program for ketamine in ALS. This achievement complements PharmaTher's existing Orphan Drug Designation (ODD) for ketamine, granted by the U.S. Food and Drug Administration (FDA), creating a powerful strategic advantage in addressing this devastating neurodegenerative disease.","length":448,"tagName":"p"},{"type":"text","content":"“The grant of this U.S. patent is a monumental achievement for PharmaTher and a critical step in solidifying our leadership position in developing novel ketamine therapies for severe neurological disorders,” said Fabio Chianelli, CEO of PharmaTher. “Combined with our Orphan Drug Designation, we have built a formidable moat around our ketamine program for ALS. This dual protection of intellectual property and regulatory exclusivity is a cornerstone of our strategy to unlock significant shareholder value as we advance towards clinical development and potential commercialization for a patient population with an urgent unmet medical need.”","length":643,"tagName":"p"},{"type":"text","content":"The Unmet Need in ALS: A Devastating Disease","length":44,"tagName":"p"},{"type":"text","content":"Amyotrophic Lateral Sclerosi...